Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation?

Authors:

Abstract
Introduction: Carvedilol is a comprehensive β1−, β2− and α1-adrenoreceptor blocker marketed as Dilatrend by F. Hoffmann-La Roche Ltd. (Roche) and as Coreg by GlaxoSmithKline for the treatment of hypertension, stable angina pectoris, post myocardial infarction with left ventricular dysfunction and all degrees of symptomatic chronic heart failure.Objectives: In this report, the pharmaceutical qualities of Dilatrend 6.25 mg, 12.5 mg and 25 mg tablets and 35 randomly selected carvedilol generic products from 20 manufacturers in 19 countries have been assessed according to the European Pharmacopoeia and the Roche specifications.Methods: The generic products were subjected to four key tests: carvedilol content, tablet hardness, tablet dissolution and purity.Results: All three Dilatrend strengths conformed to specifications. At least 17/35 (48.6%) generic products failed the specifications due to: incorrect mean carvedilol content (outside 95–105%) – three products; excess impurities (> 0.3%) – one produ...

This publication has 9 references indexed in Scilit: